Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Crinetics Pharmaceuticals Inc
Interest Income Expense
Crinetics Pharmaceuticals Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
|
Interest Income Expense
$35.6m
|
CAGR 3-Years
333%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$663m
|
CAGR 3-Years
38%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$630.1m
|
CAGR 3-Years
93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Crinetics Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
35.6m
USD
Based on the financial report for Mar 31, 2024, Crinetics Pharmaceuticals Inc's Interest Income Expense amounts to 35.6m USD.
What is Crinetics Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
68%
Over the last year, the Interest Income Expense growth was 3%. The average annual Interest Income Expense growth rates for Crinetics Pharmaceuticals Inc have been 333% over the past three years , 68% over the past five years .